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Background: The notion that epigenetic mechanisms may be central to cancer initiation and progression is
supported by recent next-generation sequencing efforts revealing that genes involved in chromatin-mediated
signaling are recurrently mutated in cancer patients.
Results: Here, we analyze mutational and transcriptional profiles from TCGA and the ICGC across a collection 441
chromatin factors and histones. Chromatin factors essential for rapid replication are frequently overexpressed, and
those that maintain genome stability frequently mutated. We identify novel mutation hotspots such as K36M in
histone H3.1, and uncover a general trend in which transcriptional profiles and somatic mutations in tumor samples
favor increased transcriptionally repressive histone methylation, and defective chromatin remodeling.
Conclusions: This unbiased approach confirms previously published data, uncovers novel cancer-associated aberrations
targeting epigenetic mechanisms, and justifies continued monitoring of chromatin-related alterations as a class, as more
cancer types and distinct cancer stages are represented in cancer genomics data repositories.
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Epigenetic control of gene expression dictates cell fate in
health and disease, and dysregulation of epigenetic sig-
nals is associated with cancer [1,2]. Two observations sup-
port pharmacological targeting of the ‘cancer epigenome’
[1]: (1) some cancer-associated epigenetic aberrations
drive cancer initiation or progression; and (2) unlike gen-
etic information, epigenetic states are reversible. Phar-
macological agents targeting with little specificity DNA
methylation and histone de-acetylation have been ap-
proved for the treatment of myelodysplastic syndrome
and lymphoma respectively [3,4], and compounds tar-
geting bromodomain-containing proteins and protein
methyltransferases have recently advanced to clinical
trials [5,6]. Cancer associated overexpression, mutation, or
aberrant recruitment of chromatin factors (defined here as
proteins that participate in the chemical modification of
DNA, histones, or control nucleosome occupancy),* Correspondence: matthieu.schapira@utoronto.ca
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unless otherwise stated.represent emerging opportunities for cancer therapy. For
instance, inhibitors of EZH2 - a histone 3 lysine 27
(H3K27) methyltransferase that is overexpressed in a
number of solid tumors and is the site of recurrent gain-
of-function mutations in lymphoma - are raising consider-
able interest as potential anti-cancer agents, and have re-
cently advanced to the clinic [5].
Chromosomal aberrations and altered expression of
chromatin factors that are recurrent in specific cancer
types have been reported in the literature, some exten-
sively, and recently reviewed [2,7-9]. Out of the recent
compilation of the 58 most frequently mutated genes in
cancer [10], we find that 16 are chromatin factors. These
aberrations can lead to the deregulation of chromatin
patterns controlling hundreds of target genes, as recently
reviewed by Plass et al. [11]. Pan-cancer analyses of the
human genome’s mutational landscape were also recently
reported [12-14]. Here, we present a pan-cancer analysis
focused on proteins that shape the human epigenome
based on the chromosomal and transcriptional landscape
of tumor samples from cancer patients available from The
Cancer Genome Atlas (TCGA) [15] and the International
Cancer Genome Consortium (ICGC) [16]. We took an
unbiased approach and focused on cancer types with larged. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are extensively rearranged. This systematic and integrated
approach identifies many oncogenic aberrations already
recorded in the literature, but also uncovers novel alter-
ations recurrently affecting chromatin factors in specific
cancer types. Overall our results provide novel insight
into the cancer epigenome revealing a tendency toward
alterations predicted to result in greater transcriptional




Chromatin factors were divided into protein families:
protein methyltransferases (PMTs), lysine demethylases
(KDMs), histone acetyltranferases (HATs), histone dea-
cetylases (HDACs), DNA methyltransferases (DNMTs),
methylcytosine oxidases (TETs), bromodomain containing
proteins (BRDs), Royal family of methyl-lysine readers
(Kme readers), PHD finger containing proteins (PHDs),
and methyl-cytosine binding proteins (MBDs). Some of
the members of these protein families are not known to
participate in epigenetic signaling, but we followed a
target-class approach and included these genes in the
analysis. Components of ATP-dependent chromatin
remodeling complexes [17] were also added to the ana-
lysis as well as histones and their chaperones. Finally,
IDH1 and IDH2, two genes that control cellular levels
of 2-hydroxyglutarate (an inhibitor of lysine and DNA
de-methylases) were included [18], for a total of 441
genes (Additional file 1: Table S1). All pre-processed,
validated mutation, and RNAseq expression data affecting
these genes in tumor samples were extracted from TCGA
(level 3 and 4) and the ICGC (mutation data only - level 3)
and grouped by cancer type (Additional file 2: Figure S1).
Changes in expression levels and mutation were measured
relative to matched normal samples from the same patient.
Cancer genomes with unusually high mutation rates (and
therefore more passenger mutations) were excluded from
the analysis (see Methods section for details). Only co-
horts with more than 100 patients passing this filter were
considered in order to calculate mutation frequencies.
Frequencies of change in gene expression were calculated
from cohorts of more than 30 patients. Chromosomal
translocations are not included in our analysis. These are
directly accessible from literature-based resources such
as the Mitelman or COSMIC databases, but we made
a deliberate choice here of avoiding data that has been
extracted from the literature.
Uneven deregulation of epigenetic target classes in cancer
As shown in Additional file 2: Figure S1 and Table 1, our
analysis retrieved a number of known cancer-associated
aberrations in chromatin factors. For instance, EZH2appears as the most frequently overexpressed protein
methyltransferase. We find that this gene is not only over-
expressed in breast and prostate cancer, as extensively
published [19], but also ranks number 44 and 94 among
the most frequently overexpressed genes in liver hepa-
tocellular carcinoma and lung squamous cell carcinoma,
respectively. Other examples include recurrent mutations
of the chromatin remodeling protein ATRX in lower
grade glioblastoma (40% of patient) [20], or DNMT3A
and TET2 in acute myeloid leukemia (25% and 8.6% of
patients, respectively) [21,22], mutations of the H3K4
methyltransferase MLL3 in 7.7% of breast cancer patients
[23], or mutations of the bromodomain containing protein
PBRM1 in 28.5% of kidney renal clear cell carcinoma [24].
Our analysis also reveals previously unreported observa-
tions. The PRDM sub-group of PMTs is overwhelmingly
repressed across multiple cancer types, suggesting tumor
suppressor activity, but PRDM12 is among the most over-
expressed genes in prostate adenocarcinoma (log2 tumor
versus matched control >1 in 66% patients). We also note
that PRDM12 is overexpressed in 21 out of 22 colon
adenocarcinoma patients (this patient cohort is not pre-
sented in our analysis because its size does not meet our
criteria for statistical significance (cohort size <30 patients),
but this exceptional ratio of 95% is still worth mentioning).
The arginine methyltransferase PRMT8 is overexpressed in
68% of thyroid carcinoma (Additional file 2: Figure S1A).
Another PMT, MLL2, and the HAT EP300 are found
mutated in 18% and 7.8% of head and neck tumors, respec-
tively (Table 1). Interestingly, L3MBTL4, a methyl-lysine
reader, is one of the most repressed chromatin factors
across all cancer types examined.
It has been argued that epigenetic mechanisms are at
the heart of cancer biology [9], and it is reasonable to
ask whether protein families that control epigenetic signal-
ing represent promising target classes for cancer prevention
and treatment. To indirectly address this question, we com-
pared the transcriptional and mutational landscapes of our
441 chromatin genes from which were excluded histones
and their chaperones (totaling 359 genes) with those of the
human kinome composed of 504 kinases (a validated target
class), and five independent sets of 359 random genes
(excluding kinases and chromatin factors) (Figure 1). We
find that the frequency of altered expression in tumor
samples is identical for kinases and random genes, but sig-
nificantly lower for chromatin factors. Since chromatin
factors contribute to regulation of the expression profile
of the entire genome, small variations in the expression
level of chromatin factors may result in greater changes in
the expression level of target genes. Inversely, we find that
chromatin factors are more frequently mutated in tumor
samples than random genes (Figure 1). Again, the ration-
ale here may be that since chromatin factors control the
transcriptional profile of the cancer genome, mutations
Table 1 Most frequently mutated or over/under-expressed chromatin factors in cancer
Gene Cancer Mutated
(%)








ATRX LGG 39.8 1.82E-11 HJURP PRAD 88 3 PRDM16 KIRP 100 14
ARID1A UCEC 32.3 8.11E-12 UHRF1 BRCA 94.7368 7 PRDM16 KIRC 95.8904 40
PBRM1 KIRC 28.5 1.76E-11 TDRD1 PRAD 84 14 KAT2B HNSC 82.9268 55
DNMT3A LAML 25.4 3.96E-12 DPF1 HNSC 87.8049 25 JMJD5 LIHC 88 56
MLL2 LUSC 19.1 6.39E-05 HJURP BRCA 91.2281 29 TDRD10 LUSC 100 57
ARID1A STAD 18.1 2.63E-11 HJURP LUAD 94.7368 31 MECOM KIRC 95.8904 62
MLL2 HNSC 17.7 1.94E-11 HJURP LIHC 96 34 L3MBTL4 PRAD 76 73
CHD4 UCEC 13.3 0.000958 ASF1B BRCA 91.2281 37 ASXL3 THCA 78.7879 81
STK31 SKCM 11.9 0.049702 UHRF1 KIRP 90 37 CECR2 THCA 80.303 83
NSD1 HNSC 10.8 1.89E-11 ORC1 LIHC 94 40 ZCWPW2 HNSC 80.4878 84
SETD2 KIRC 9.8 1.76E-11 EZH2 LIHC 94 44 ZGPAT LIHC 82 141
TET2 LAML 8.6 2.42E-11 ASF1B KIRP 90 45 TDRD10 BRCA 85.0877 154
EP300 HNSC 7.8 0.008196 HJURP LUSC 100 47 MECOM KIRP 93.3333 162
MLL3 BRCA 7.7 1.95E-11 UHRF1 LUSC 100 68 ACTA1 PRAD 70 194
SMARCA4 LUAD 7.4 2.99E-08 ORC1 LUAD 92.9825 72 CBX7 BRCA 83.3333 218
SETD2 LUAD 7 0.006858 ORC1 LUSC 100 79 TDRD9 THCA 71.2121 261
KDM5C KIRC 5.8 3.75E-11 ASF1B LUSC 100 90 TDRD6 BRCA 81.5789 277
ARID1A LUAD 5.7 0.001823 EZH2 LUSC 100 94 CHD5 PRAD 68 277
SMARCA4 LGG 4.5 0.035502 UHRF1 LUAD 89.4737 101 KIAA1045 BRCA 80.7018 298
KDM5C LUAD 4.4 0.091808 HIST1H3D BRCA 85.9649 102 CBX7 LUAD 85.9649 342
ARID1A BRCA 2.9 0.000117 TCF19 LIHC 88 102 SCML2 THCA 69.697 344
PHF6 LAML 2.5 0.001759 HJURP KIRP 83.3333 107 L3MBTL4 BRCA 79.8246 346
HIST1H1B HNSC 2.3 0.084637 CECR2 PRAD 72 107 DPF3 LIHC 72 364
HIST1H3B BRCA 1.1 9.81E-05 HIST1H3H BRCA 85.9649 109 CECR2 KIRC 83.5616 388
UHRF1 LIHC 88 109 PRDM16 LUSC 92 410
Values indicate the frequency of cancer patients where a gene is mutated (non-silent mutations only), where Log2(mRNA tumor/matched control) >1 for overexpression,
or < -1 for underexpression. All data were extracted from TCGA and the ICGC. Patient cohorts are greater than 30 for overexpression and 100 for mutations. Hypermutated genomes and other sources of noise were excluded (as


















Figure 1 Average over-/underexpression frequencies and mutation rates of chromatin factor families. Top: Averages were calculated by
summing the frequencies of overexpression or underexpression, or number of mutations per kilobase for each gene and dividing by the total
number of genes in the family. The list of 359 chromatin factors is composed of the 441 genes listed in Additional file 1: Table S1 from which
histones and histone chaperones were removed. Numbers were also calculated for five independent sets of 359 random genes for comparison.
Log2(mRNA tumor/matched control) cut-offs of 2 and -2 were used for over- and underexpression, respectively, for better separation and
comparison of transcription profiles.
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pact on the expression of a combination of genes involved
in cell fate, survival, or DNA damage response.
Finally, we note that histones and their chaperones are
dramatically overexpressed in cancer (Figure 1). This
probably reflects strong dependence on histones in a
highly replicative cellular environment, such as a tumor.
The number of histones frequently overexpressed in can-
cer could also be accentuated by the fact that histones are
clustered within restricted genomic areas that may be co-
regulated. Among enzymes, protein methyltransferases arethe most frequently overexpressed across the cancer
patient cohorts examined (Additional file 3: Figure S2).
Together, these results show that chromatin factors
are more frequently mutated in cancer than random
genes, but their expression profile is less variable.
H3K4 and H3K36 methylation are preferentially targeted
by mutations
It has been proposed that site-specific missense mutations
that recur across a sizable cohort of cancer patients are
indicative of an oncogenic role for the targeted gene, while
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more likely to act as tumor suppressors [25]. A radiomet-
ric rule was suggested in which oncogene candidates
should be affected at a recurrent position by at least 20%
of missense mutations [25]. Following a similar principle,
we searched our 441 chromatin factors for mutation hot-
spots (Figure 2A,B). As before, this analysis is limited by
the depth and breadth of mutational coverage available.
For instance, we did not have access to lymphoma data,
and failed to retrieve known Y641 mutants that increase
the trimethylase activity of EZH2 in this cancer type
[26,27]. However, acute myeloid leukemia (AML) is cov-
ered by our analysis, and we did retrieve the well-known
mutation hotspot at position R882 of DNMT3A [21]: 21
of the 54 mutations found on this gene in AML patients
map at this position (Figure 2A,B). Similarly, the well-
known mutation hotspot at R132 of IDH1 recurrent in
lower grade glioblastoma (LGG) and AML is observed.
We also identified mutation hotspots that, to our know-
ledge, have not been previously reported (Figure 2A,B).
For instance, genes coding for the histone variant H3.1,
are mutated in 17 out of 270 head and neck squamous cell
carcinoma samples (HNSC), and four of these mutations
replace a lysine with methionine at position 36 (twice in
HIST1H3C, once in HIST1H3E and once in HIST1H3I)
suggesting that H3K36M is an oncogenic mutation that
drives tumor initiation or progression in a fraction of
HNSC patients. Interestingly, an H3K27M mutation is ob-
served in 80% of diffuse intrinsic pontine gliomas and 22%Figure 2 Mutation frequency and mutation hotspots. (A) Percent of m
versus the total number of mutations found across the gene in the same c
the hotspot. (B) Mapping of mutation hostpots on the domain architecture
colorectal cancer on the domain architecture and 3D structure of MLL3. Th
Two of the mutations that can be mapped on 3D structures are targeting re
were excluded from the analysis as detailed in the Methods section.of non-brain stem gliomas [28]. The H3K27 methylating
PRC2 complex is recruited and trapped by the H3K27M
peptide, resulting in an overall decreased methylation of
H3K27 at ectopic sites [29]. The authors demonstrated
that H3K36M and H3K9M transgenes also decreased
overall amounts of H3K36me2,3 and H3K9me2,3, re-
spectively. This suggests that the H3K36M mutation
recurrently observed in HNSC patients may result in
reduced levels of methylation at H3K36. We also found
a H3K36M mutation in a colorectal cancer sample, sug-
gesting that this mechanism may extend to other cancer
types. Though statistically significant, we note that the
H3K36M mutation rate of 24% out of the 6.2% HNSC
samples carrying a mutation at H3.1 remains low. As a
comparison, over 40% of cutaneous melanoma samples
carry a mutation in BRAF, 90% of which are at the hotspot
V600E [30].
Another histone, H2B is mutated in seven out of 377
glioblastoma multiform patients, resulting in a G53D
mutant in three cases (in HIST1H2BE, HIST1H2BL and
HIST1H2BF) (Figure 2A,B). This mutation places an
acidic residue in the minor groove of the DNA wrapped
around the histone octamer (Additional file 4: Figure S3),
which should destabilize nucleosomal H2B, and possibly
nucleosome fluctuation or chromatin architecture.
The PWWP domain is a methyl-lysine reading module
that generally binds di- or tri-methylated H3K36. We find
that WHSC1, an H3K36 di-methylase that harbors two
PWWP domains, is mutated in eight HNSC samples. Inutations targeting a conserved residue on a gene (hotspot) are plotted
ancer type. Color-coding indicates the total number of mutations at
of selected proteins. (C) Mapping of missense mutations found in
ree mutations are mapping on an N-terminal cluster of PHD fingers.
sidues that are necessary for histone binding. Hypermutated genomes
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G944 of the C-terminal PWWP domain (Figure 2B).
This results in deletion of the C-terminal helix of the
WHSC1 PWWP domain, expected to cap the methyl-
lysine binding aromatic cage, and may also cause trunca-
tion of the methyltransferase domain of WHSC1, located
on a downstream exon. In both cases, alteration of
H3K36me2 mediated signaling is expected. We find that
the H3K36M mutation and WHSC1 frameshifts are mu-
tually exclusive in HNSC tumor samples. Both aberrations
are expected to affect H3K36me2 signaling and may rep-
resent alternate pathways to the same molecular endpoint.
While mutation hotspots are expected to reveal onco-
genes, tumor suppressors are generally targeted by
mutations that are more distributed over the gene in
cancer. The tumor-suppressor pattern is predominant
in chromatin factors (Figure 2A). We find that the
H3K36 trimethylase SETD2 and dimethylase NSD1 are
among the top 25 most mutated chromatin factors in
kidney, head and neck, and lung carcinoma (Table 1).
The H3K4 methyltransferases MLL2 and MLL3 are also
among the most mutated, with no apparent mutation
hotspot, in lung, head and neck, and breast cancers and
are therefore tumor suppressor candidates in these tu-
mors. In total, six of the most mutated genes in various
cancer types methylate H3K4 or H3K36 (Additional file
2: Figure S1A, Table 1).
Mutations that are not located at a hotspot appear to
be more evenly distributed on target genes, but mapping
some of these mutations onto protein structures can re-
veal ingenious residue targeting. For instance, MLL3
missense mutations are found in eight out of 36 colorec-
tal cancer patients from an ICGC study. Mapping these
mutations on the domain architecture of the protein
shows that three are located on the N-terminal triple-
PHD finger of the protein (Figure 2C - Top). An apo
structure of PHD1,2 of MLL3 was solved (PDB code
2YSM), as well as a structure of the tandem PHD do-
main of DPF3, a close homolog (40% sequence identify),
in complex with a histone peptide (PDB code 2KWJ).
Superimposing the two structures allows positioning of
the histone peptide relative to the MLL3 PHD fingers.
Importantly, we observe that D328 makes critical elec-
trostatic interactions with both H3K4 and H3K9 in the
DPF3 complex, and is conserved in MLL3 (corresponding
residue: D400 - Figure 2C - Bottom). Intriguingly, D400N
is one of the three mutations affecting the triple PHD
finger of MLL3 in colorectal cancer, and, based on these
structural observations, should significantly affect histone
binding. A second mutation is C347G. This cysteine is
one of the four residues coordinating the Zn atom that
holds the first PHD finger together (Figure 2C). The
C347G mutation will irremediably affect the structure of
this domain, expected to participate in substrate binding.Somatic mutations affecting MLL3 in colorectal cancer
seem therefore to target with high precision residues
involved in recruiting the enzyme to appropriately
marked loci.
Selective targeting of H3K4 and H3K36 methylation
by oncogenic mutations was also observed in other stud-
ies that are not yet available from TCGA; for instance,
mutations in SETD2 and genes affecting H3K36 methyla-
tion are recurrent in high-grade gliomas [31]. Together,
these results show that H3K36 and H3K4 mediated
signaling is highly targeted in cancer via hotspot mu-
tations of oncogenes and random mutation of tumor
suppressors.
Chromatin factors are involved in a brain tumor-specific
gene mutation network
To identify cancer-associated chromatin factor alterations
that are either synergistic or redundant, we searched for
co-occurring and mutually exclusive mutation patterns,
respectively (Additional file 5: Table S2). Co-occurrence or
mutual exclusion with non-chromatin factors was also
considered. We find that mutations are co-occurring in
ATRX, TP53, and IDH1, and that these are mutually exlu-
sive with mutations in PTEN and EGFR in glioblatoma
multiform (GBM) and lower grade glioma (LGG) (Figure 3;
Additional file 5: Table S2). For example, TP53 is mutated
in 50% of all LGG samples, but in 95% of the 80 ATRX-
mutated samples.
The mutational landscape of adult and pediatric brain
cancer has been extensively analyzed (we did not have
access to pediatric data in this work) [32,33]. Interestingly,
it was found that mutations in IDH1, ATRX, or TP53
were recurrent only in glioma-CpG island methylator
phenotype-positive tumors (a phenotype probably attribu-
table to the competitive inhibition of TET demethylases,
following accumulation of 2-hydroxyglutarate caused by
IDH1 mutation), while mutations in EGFR and PTEN were
only observed in other tumor subtypes, which is in
agreement with the pattern that we observe [32]. An
important mutation that is missed in our exome-
centric analysis is an upregulating mutation in the pro-
moter of the telomerase reverse transcriptase (TERT),
observed in 58% to 84% of primary glioblastomas, sug-
gesting that telomere lengthening plays an important
role in tumor growth [34]. Interestingly, ATRX is
required for accumulation at telomeres [35], and
ATRX mutations promote telomere lengthening and
cellular proliferation [36]. Similarly TP53 deficiency
favors telomere lengthening [37]. This suggests comple-
mentary pressures towards an oncogenic pathway depend-
ing on telomere lengthening by mutations co-occurring at
ATRX, TP53 and (hypothetically) IDH1 in adult brain
tumors where the PTEN/EGFR surface signaling axis
is not altered.
Figure 3 Mutually exclusive and co-occurring mutations in brain cancer. (A) Distribution of mutations in ATRX, IDH1, TP53, EGFR, and PTEN
across 283 lower grade glioma (LGG) and 288 glioblastoma multiform (GBM) patients. Each column is a patient. Red: mutated; white: not mutated.
(B) Co-occurrence (orange) and mutual exclusion (blue) patterns suggest that genetic aberrations can target two distinct axes: ATRX/IDH1/TP53 and
EGFR/PTEN. LGG and GBM samples with more than 110 and 164 mutated genes, respectively, were excluded from the analysis (cutoffs derived from
mutation burden distribution, detailed in the Methods section).
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sion in lower grade glioma between ATRX and CIC, a
transcriptional repressor that may play a role in develop-
ment of the central nervous system [38], and mutual ex-
clusion in uterine corpus endometrial carcinoma between
mutations at TP53 and SWI/SNF remodeling complex
protein ARID1A (Additional file 5: Table S2). This is in
agreement with a role in maintenance of DNA integrity
for both TP53 and the SWI/SNF complex.
Alteration of chromatin factors involved in replication
and genome stability
We find that some of the changes observed in the cancer
epigenome can be associated with a hyperproliferative
phenotype, a hallmark of cancer. For instance, histones
are twice more frequently overerexpressed than random
genes and five to 10 times less frequently underexpressed
or mutated in cancer (Figure 1). Additionally, the histone
chaperones ASF1B and CHAF1A/B, that are involved
in replication-dependent nucleosome assembly [39], are
among the most overexpressed histone chaperones, while
replication-independent chaperones that maintain nucleo-
some density and are involved in gene transcription andepigenetic memory, such as DAXX and HIRA [40] are not
over-expressed (Figure 4; Additional file 2: Figure S1A,B;
Table 1). We also find that the only two proteins known
to act as direct links between histone methylation
and the DNA replication machinery, ORC1 (that binds to
H4K20me3 and recruits the origin of replication com-
plex at replication origins [41]) and UHRF1 (that binds
H3K9me3 and recruits DNMT1 to hemi-methylated cyto-
sines [42]), are among the five most frequently overex-
pressed chromatin factors across all cancer types studied
(Additional file 2: Figure S1B).
Another histone chaperone that is significantly overex-
pressed - actually the most frequently overexpressed chro-
matin factor in cancer - is HJURP, a chaperone of the
histone H3 variant CENP-A, which facilitates aneuploidy
and genome instability, another hallmark of cancer [43]
(Additional file 2: Figure S1B; Table 1). Expression level
of HJURP was previously reported to correlate with
glioblastoma cell survival, and was found to be a pre-
dictive biomarker for sensitivity to radiotherapy in breast
cancer [44,45].
The DNA repair machinery is an important factor in
genome instability, and we find that it is repeatedly
Figure 4 Alterations of chromatin remodeling complexes and histone chaperones. Transcription and mutation heatmaps illustrate the
frequency of alteration in components of chromatin remodeling complexes and histone chaperones.
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cancer. SETD2 is among the most mutated chromatin fac-
tors in kidney renal clear cell and lung adeno carcinomas
(Table 1). SETD2 trimethylates H3K36, a mark that regu-
lates DNA mismatch repair through recruitment of the
PWWP domain of MSH6 [46]. Additionally, SETD2 was
recently shown to act as a guardian of transcriptome in-
tegrity by preventing intragenic transcription initiation
[47]. The PMT SETMAR includes both methyltransferase
and transposase domains, and both domains are essen-
tial for double-strand break repair [48]. We find that
SETMAR is recurrently underexpressed in tumor sam-
ples, including in 54% of HNSC and 78% of kidney renal
clear cell carcinoma patients (Additional file 2: Figure S1).
ATRX, ARID1A, PBRM1, and SMARCA4 are also among
the most frequently mutated chromatin factors in cancer
(Table 1; Figure 4), and are all components of the chro-
matin remodeling complex SWI/SNF, which has been
shown to facilitate double-strand break repair [49].
Additionally, ATRX is responsible for the incorporation
H3.3 at telomeres, and its mutation can cause alternative
telomere lengthening, associated with increased genomic
instability [20].These observations strongly suggest that genetic or
transcriptional aberrations targeting chromatin factors
in cancer favor replication and contribute to genome
instability. We note a potential synergy between these
targeted events and other mechanisms that also link
epigenetic mechanisms to alteration of DNA maintenance
in cancer. These include hypermethylation at DNA pro-
moter regions of genes involved in DNA repair, or direct
control of regional mutation rates through chromatin
organization [1,50].
Gene amplification rarely drive transcriptional alterations
of chromatin factors
Cancer genomes generally have large numbers of ‘pas-
senger’ mutations and a small number of driver genetic
events. Additionally, cancer-associated overexpression
does not necessarily imply disease-relevance. However,
when overexpression is caused by a chromosomal aberra-
tion, disease-relevance is more likely [51,52]. To identify
candidate drivers affecting epigenetic mechanisms, we
looked for correlations between copy number gains and
overexpression of chromatin factors in cancer samples
compared with matched normal samples [51,52].
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sion is not correlated with copy number gain. For in-
stance, EZH2 and UHRF1 are two of the most frequently
overexpressed chromatin factors but are rarely amplified
in cancer (Figure 5A,B). This comes as no surprise, since
multiple factors can affect the transcriptional levels of a
gene, such as DNA methylation of promoter or enhancer
elements, expression levels of ncRNA, transcription fac-
tors or chromatin factors controlling expression of this
gene. Nevertheless, we do find that gene overexpression
correlates remarkably with gene amplification in a few
cases. Clear correlation is observed for the H3K9 trimethy-
lase SETDB1, significantly amplified and overexpressed in
16% of lung adenocarcinoma samples (Figure 5C). Amplifi-
cation of the SETDB1 gene in lung cancer was recently
shown to contribute to lung tumorigenesis, and shRNA-
mediated depletion of SETDB1 in amplified cells reduced
tumor growth in a mouse xenograft model [53]. Another
example is the H3K36 dimethylase WHSC1L1/NSD3
amplified and overexpressed in 18% and 8% of lung squa-
mous cell and breast invasive carcinomas, respectively
(Figure 5D). WHSC1L1 is in the 8p11.2-p12 amplicon,
previously reported in 10% to 15% breast cancers, and
associated with poor prognosis [54]. This amplicon in-
cludes other genes that may also act as oncogenes, such as
FGFR1. Interestingly, knockdown of WHSC1L1 results in
profound loss of growth survival of 8p11-12 amplified
breast cancer cells, but not control MCF10A cells
[55]. These results suggest that amplification ofWHSC1L1
drives cancer in a subset of breast cancer patients.Figure 5 Correlation between mRNA expression and copy number va
across different cancer types (blue bars - log2(mRNA(tumor/matched normal)
GISTIC =2 and log2(mRNA(tumor/matched normal)) >1). (C-F) Box plots distri
normal))) in tumor samples grouped by GISTIC values (that is, levels of copy nWHSCI1L1 overexpression is even more frequent in lung
squamous cell carcinoma and its amplification may also be
a driving event in a subset of patients. Among our 441
chromatin factors, the most frequently amplified/overex-
pressed genes were ACTL6A, a component of the SWI/
SNF chromatin remodeling complex that is overexpressed
and amplified in 53% of lung squamous cell carcinoma
samples, and FXR1, a gene that codes for a Tudor domain
containing protein that is also overexpressed and ampli-
fied in 53% of the same tumor type. In both cases, expres-
sion levels correlate strongly with copy number gains
(Figure 5E,F). Both genes are actually located at the 3q26-
29 amplicon, which is prevalent in lung squamous cell
carcinoma [56]. Integrative genomic analysis pointed at
genes involved in ubiquitylation pathway as candidate
drivers, while microarray expression profiles indicated
that FXR1 was one of three genes from the amplicon
consistently overexpressed in lung squamous cell carcin-
oma [57,58]. Of the close to 250 genes located at the
3q26-29 amplicon, we find that ACTL6A and FXR1 are
among the 10 and 30 most frequently overexpressed genes
in this cancer type, respectively. Vulnerability of cancer
cells to ACTL6A or FXR1 knock-out would be necessary
to characterize the role of these genes in lung squamous
cell carcinoma.
Together, these results show that overall copy number
variation do not appear to drive transcriptional de-
regulation of most chromatin factors and are therefore
likely to be passenger events in cancer. Nevertheless, in
rare cases, recurrent gene amplifications do appear toriation. (A-F) Recurrence of gene overexpression in tumor samples
) >1) compared with recurrence of gene amplification (red bars -
bution of changes in gene expression levels (log2(mRNA(tumor/matched
umber variation).
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samples. Genetic or pharmacologic targeting of these
genes will be necessary to further investigate their role in
tumor initiation and progression.
Discussion
Recent landmark next-generation sequencing campaigns of
large cancer patient cohorts repeatedly revealed recurrent
alterations of genes involved in epigenetic mechanisms
[20,23,24,59-61]. The data associated with most of these
and other unbiased cancer genomic projects were depos-
ited in TCGA and the ICGC repositories, and made pub-
licly accessible to the scientific community [14,16]. Here,
we took a systematic approach to analyze this aggregated
data across a list of 441 genes involved in chromatin-
mediated signaling.
Specific combinations of post-translational modifica-
tions of DNA and histones at distinct genomic elements
control chromatin compaction, nucleosome occupancy,
and gene activation status [62]: histone acetylation and
H3K4 di- or tri-methylation at promoters, H3K4 mono-
methylation at enhancers and tri-methylation of H3K36
as well as DNA methylation in gene bodies are asso-
ciated with transcriptionally active genes. Promoters tri-
methylated at H3K4 and H3K27 are thought to be in a
state that is transcriptionally repressed, but ‘poised’ for
rapid activation upon demethylation of H3K37. Finally,
tri-methylated H3K9 and methylated DNA at enhancers,
or a combination of these two marks with trimethylatedFigure 6 Mutational and transcriptional alterations associated with ac
dashboard reflects the effect of epigenetic states on transcriptional activati
are shifting the epigenetic machinery towards a transcriptionally repressed
simplify the list, Log2(mRNA tumor/matched control) cutoffs of 1 and -1 w
shown for enzymes writing or erasing activating (H3K4me3, H3K36me3) or
methylating or demethylating DNA as well as UHRF1.H3K27 at promoters, is associated with gene silencing
(Figure 6A,B).
Intriguingly, we find that enzymes that deposit histone
marks associated with gene activation, such as the H3K4
trimethylases MLL1-4 and SETD1A/B, or the H3K36 tri-
methylase SETD2 are more often repressed and mutated
in cancer (Figure 6C). On the other hand, enzymes that
deposit repressive histone marks, such as the H3K9
trimethylases SETDB1 or SUV39H1/2, and the H3K27
trimethylase EZH2 are overexpressed in most cancer
types studied. The trend is not as clear for demethylase,
but we note that KDM5B, which removes the activating
mark H3K4me3, is significantly overexpressed in five of the
eight cancer types studied and never repressed, while the
H3K27me3 demethylases KDM6A/B are repressed in most
cancer types (Figure 6C). Alterations in genes regulating
histone methylation appear therefore to be biased towards
silencing histone marks. The functional relevance of this
observation is unclear. We note that alterations of genes
regulating DNA methylation do not follow a similar trend
(Figure 6C), and that transcription levels are not repressed
in tumor samples when averaging across the whole genome
(Additional file 6: Figure S4). In this regard, it is unlikely
that a general trend in the control of transcription applies
across all tumors, considering the divergence in molecular
mechanisms driving different cancer subtypes.
Currently approved epigenetic drugs are DNMT and
HDAC inhibitors against myelodysplastic syndrome, acute
myeloid leukemia, and lymphoma. With the exceptions oftivating and repressive epigenetic marks. (A, B) The epigenetic
on status [62]. Most alterations recurrently observed in cancer patients
state (to focus on transcriptional variations of high-amplitude and
ere used for over- and underexpression, respectively). (C) Heatmaps are
repressive (H3K9me3, H3K27me3) histone marks, and for enzymes
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cancer types studied here, and DNMT3A which is highly
mutated in LAML, we do not see notable mutation rates
or cancer-associated changes in expression level for
DNMTs and HDACs (Additional file 2: Figure S1). We
also note that the mode of action of these first generation
drugs remains unclear and their toxicity profile mediocre.
Some of the emerging epigenetic drugs, such as bromo-
domain, protein methyltransferase, or IDH1 inhibitors,
are targeting patient group with clear oncogenic chro-
mosomal aberrations such as gene fusions at BRD4 and
MLL1, or mutations at IDH1 [6,63,64]. Translocations are
not included in our analysis, but IDH1 mutations are high
on our chromatin factor mutation landscape (Additional
file 2: Figure S1A). Other peaks, such as ATRX mutations
in lower grade glioma or ARID1A mutations in endomet-
rial cancer and stomach adenocarcinoma may represent
other points of entry for therapeutic intervention.
Conclusions
The refined complexity of chromatin as a signaling plat-
form, and its dysregulation in cancer, can only be
dissected through systematic identification and functional
characterization of all chromatin factors, in specific tissue
types, and at specific stages of cancer progression. Here,
we apply a reductionist approach to identify general trends
associated with protein families or chromatin complexes
that are primary determinants of the cancer epigenome.
This analysis is restricted by the limited but rapidly grow-
ing number of cancer types that are represented at TCGA
and the ICGC repositories. It is also limited by restrictions
that we imposed to focus on statistically significant patient
cohorts and on non-hypermutated genomes (see Methods
section for details). It has been proposed that most
epigenetic-associated mutations are observed in hemato-
logical, in pediatric, or in rare and aggressive variants of
solid tumors [9]. It was also noted that, contrary to the
general pattern identified here, H3K4me3 and H3K36me3
marks are upregulated during epithelial to mesenchymal
transition, an important step in cancer progression [9]. As
the volume of cancer genomics data grows, future analysis
similar to the one presented here should capture with
more accuracy epigenetic transformations underlying
distinct types and stages of cancer.
Methods
Data access
All raw data analyzed can be accessed and downloaded
via the Broad TCGA GDAC Firehose (http://gdac.broad
institute.org/) or the ICGC data portal (http://dcc.icgc.org/).
Somatic mutation, copy number variation, RNASeq gene
expression, and DNA methylation data downloaded via
TCGA’s Firehose was extracted from the ‘stddata Run’ and
is pre-processed. This means the data have been mappedto genes, genomic locations, and a variety of auxiliary data
has been added (ex. Amino acid change for mutation data).
This type of pre-processed data is referred to as ‘Level 3’
data using TCGA’s nomenclature. Only pre-processed
somatic mutation data (version 12) referred to as ‘Simple
Mutation’ were downloaded from the ICGC data portal.
Further analyzed data, known as Level 4’, are extracted for
somatic mutation and copy number data from the ‘ana-
lyses run’. Level 4 data are produced by taking level 3 data
and running an algorithm that further isolates statistically
significant alterations. For mutation data the algorithm
used is MutSigCV [65], while GISTIC 2.0 [66] is used for
copy number data.
Cancer types
In most cases, nomenclature and abbreviations of cancer
types used at TCGA and the ICGC were preserved. These
are TCGA: BRCA: invasive breast carcinoma, COAD:
colon adenocarcinoma, COADREAD: colon and rectum
adenocarcinoma, GBM: glioblastoma multiforme, LUAD:
lung adenocarcionma, LAML: acute myeloid leukemia,
HNSC: head and neck squamous cell carcinoma, KIRC:
kidney renal clear cell carcinoma, KIRP: kidney renal
papillary cell carcinoma, LGG: lower grade glioma, LUSC:
lung squamous cell carcinoma, OV: ovarian serous cysta-
denocarcinoma, SKCM: skin cutaneous melanoma, STAD:
stomach adenocarcinoma, THCA: thyroid carcinoma,
LIHC: liver hepatocellular carcinoma, PRAD: prostate
adenocarcinoma, and UCEC: uterine corpus endometrioid
carcinoma (The Cancer Genome Atlas Network). For ICGC:
breast carcinoma, breast cancer, colorectal cancer, glioblast-
oma multiforme, lung adenocarcinoma, myeloproliferative
disorders, chronic lymphocytic leukemia, liver cancer,
pediatric brain tumors, and pancreatic cancer. Mutation
data downloaded from the TCGA were excluded from the
ICGC downloads. In a few cases, distinct patient cohorts
from TCGA and the ICGC were affected by similar cancer
types. These were merged as follows: breast cancer, breast
carcinoma cohorts from ICGC and BRCA cohort from
TCGA, colorectal cancer, COADREAD and READ cohorts
from TCGA, glioblastoma multiforme cohort from ICGC
and GBM cohort from TCGA, lung adenocarcinoma
cohort from ICGC and LUAD cohort from TCGA.
Somatic mutations
Somatic mutations relative to the reference human gen-
ome (hg18 for COAD/READ, LAML and OV; hg19 for
all other cancer types) are extracted from sequencing
data using complex algorithms (which are not discussed
here since this pre-processing step is conducted at
TCGA and the ICGC) and linked to anonymized patient
ID, affected gene/transcript, chromosomal position, and
nucleotide/amino acid change. For each patient, the
overall number of genes mutated within the tumor sample
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with unusually high number of mutations. This cutoff
differs across cancer types based on their mutation level.
In order to determine this cutoff, for each cancer type
cohort analyzed, the number of mutated genes was plot-
ted across all patients and a value equivalent to the
mean +3*standard deviation of the normal distribution was
used to set the cutoff (Additional file 7: Figure S5). Any
tumor with more mutated genes than the cutoff set for
that cancer type was excluded from the analysis when ana-
lyzing mutations hotspots and mutation co-occurrence/
mutual exclusion, that is, when comparing each individual
patient. In other analyses, where the readout is the fre-
quency of mutation, we rely on MutSigCV, which accounts
for background mutation rates, gene length, and other
source of noise (q value ≤0.1) [65]. No normal distribution,
but a continuum of highly mutated genomes were found
for lung squamous cell carcinoma and skin cutaneous mel-
anoma, and these two patient cohorts were therefore
excluded from our recurrent mutation analysis. Since the
frequency of mutation of a single gene is low, cohorts that
were less than 100 patients were excluded. Additionally,
mutation frequencies that were derived from less than
three mutations, and mutations at poly-Q regions were ex-
cluded from further analysis to reduce noise levels. The
mutation frequencies that we observed for our 1,000
random genes across diverse cancer types differs from that
previously published [25]. We attribute this apparent
discrepancy due to the fact that level 3 mutation data that
we obtain from TCGA and the ICGC are pre-processed to
eliminate false-positives. This is in agreement with previ-
ous work showing that some cancer types are particularly
enriched in false mutation calling. For instance, pre-
processing can reduce the number of frequently mutated
genes in lung cancer from 450 to 11 [65].
Co-mutation analysis
Using 2 × 2 contingency tables we produced fisher P
values, odds ratios, and 95% confidence intervals for
each possible pairing of genes present in Additional
file 1: Table S1. Two-sided Fisher’s exact test was used to
produce P values and only those that were ≤0.05 were
considered significant. Odds ratios and confidence inter-
vals were produced as previously reported [67]. Odds ra-
tios >1 were considered to imply mutation co-occurrence,
while odds ratios <1 implied mutation mutual exclusion.
Gene pairs with a confidence interval containing 0 was
considered statistically insignificant.
mRNA expression
TCGA level 3 RNASeq gene expression data were down-
loaded from the Broad Institute’s Firehose (RNASeq V2
data). Only data from patients with matched tumor and
normal samples were used. Cancer types with cohortsunder 30 patients were excluded. This threshold is more
permissive than the 100 patient cohort used for somatic
mutations, as frequencies of transcriptional changes in
tumor samples are typically an order of magnitude higher
than mutation frequencies. RSEM values are used to
quantify mRNA expression levels [68]. A log2 fold change
in gene expression is calculated from RSEM values of
tumor and matched normal samples as follows:
log2 fold change ¼ Log2ðRSEM tumor½ 
 RSEM matched normal½ Þ
Frequencies were calculated for each gene and cancer
type as the percentage of patients with a log2 fold change
greater than 1 for overexpression or lower than -1 for
underexpression.Average frequencies in over-/underexpression and
mutation across protein families
Average frequencies in over-/underexpression and muta-
tion across protein families (Figure 1) were generated for
each cancer type by summing frequencies shown in
Figure 1 (after changing the Log2 cutoff from 1 to 2 to
focus on transcriptional changes of higher amplitude)
and dividing by the total number of genes present within
the indicated protein family.Copy number variation
GISTIC values are used to evaluate copy number variations
relative to the reference genome (hg18 for COAD/READ,
LAML and OV; hg19 for all other cancer types) [66]. GIS-
TIC values of 1 and 2 indicate moderate and high copy
number gains, respectively, while values of -1 and -2 indicate
hetero- and homozygous deletions, respectively. All GISTIC
copy number data are directly downloaded from TCGA’s
Firehose interface (level 4 data). Anonymous patient ID pro-
vided by TCGA was used to determine patients where both
GISTIC copy number and matched-control RNASeq gene
expression data were available. Corresponding patient co-
horts with fewer than 15 patients were excluded. These
data were used to find correlations between copy number
variation and gene expression levels in tumor samples. For
interested readers, we made correlations for all cancer
types available on the Chromohub website [69].Identification of mutation hotspots
Mutation hotspots were defined as aminoacids affected
by a minimum of three mutations representing at least
20% of non-silent mutations for that gene in a given cancer
type. Highly mutated genomes were ignored, as previously
specified.
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Additional file 1: Table S1. Four hundred and forty-one chromatin
factors used in this study and their respective association with epigenetic
protein families.
Additional file 2: Figure S1. Mutation and transcription heatmaps of
chromatin factors. Color codes illustrate the frequency of cancer patients
where (A) a gene is mutated (non-silent mutations only), (B) where Log2
(mRNA tumor/matched control) >1 for overexpression, and (C) where
Log2(mRNA tumor/matched control) <-1 for underexpression. All data
were extracted from TCGA and the ICGC. (D) Color codes indicate how a
gene ranks in the genome based on the frequency with which it is
over-/underexpressed in cancer. Patient cohorts are greater than 30 for
overexpression and 100 for mutations. Hypermutated genomes and other
sources of noise were excluded (detailed in the Methods section).
Additional file 3: Figure S2. Average over-/underexpression frequencies
and mutation rates of chromatin factor families. Averages were calculated
as in Figure 1.
Additional file 4: Figure S3. Mapping of the H2B G53D mutation on
the nucleosome structure. An aspartate was modeled at position 53 of H2B
in the structure of the human nucleosome (PDB code 3AFA). The histone
octamer is shown as ribbons (H2B is in cyan). DNA is shown as a mesh
colored according to its electrostatic potential (red: electronegative).
Additional file 5: Table S2. Co-occurring and mutually exclusive
mutations. First tab: all genes. Second tab: focused on ATRX, IDH1, TP53,
PTEN, and EGFR in LGG and GBM.
Additional file 6: Figure S4. Overall change in expression in tumor
samples presenting a genetic or transcriptional aberration affecting a
specific chromatin factor. Patient cohorts are groups within box plots
where log2(gene expression tumor/matched control) is averaged across
the human genome. Cohort sizes for each boxplot are indicated in
parenthesis. Light blue: indicated chromatin factor is repressed in tumor
samples (log2 <-1). Red: indicated chromatin factor is mutated in tumor
samples.
Additional file 7: Figure S5. Exclusion of hypermutated genomes was
derived for each cancer type from the distribution of the number of
mutated genes per cancer patients. The normal distribution section of
the curve was used to calculate a cutoff (indicated with a red vertical bar)
as the mean of the normal distribution +3 standard deviations. Genomes
with more genes mutated than this cutoff were excluded throughout
this work. The resulting cutoffs and size of patient cohorts are indicated
in the summary table.
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